Evolus, Inc.

Company EOLS

Last mentioned: Mar 5, 2026

Timeline

Invalid Date
Evolysse Launch

Anticipated commercial rollout of the Evolysse dermal filler portfolio in the U.S.
Mar 4, 2026
Earnings Release

Company reports Q4 beat and issues bullish 2026 revenue guidance.
Dec 31, 2025
Q4 Fiscal Close

Evolus concludes its strongest fiscal year to date with record Jeuveau sales.

Stories mentioning Evolus, Inc. 1

Evolus Surges on Q4 Beat as Jeuveau Gains Ground in Medical Aesthetics

Evolus reported record Q4 2025 financial results, triggering a significant stock rally following a revenue beat and robust 2026 guidance. The company's performance underscores the resilience of the medical aesthetics market and the growing adoption of its flagship neurotoxin, Jeuveau.

Mar 5, 2026 4 sources